Stick With General Moly Inc. (GMO). The Bull Are Alive And Well


    Bridgeway Capital Management, Inc.. recently announced the acquisition of new stake in General Moly Inc. (AMEX:GMO). This fresh investment now brings its stake to 0.36% valued currently at $0.12 million. In addition, Renaissance Technologies LLC raised its holdings by 0.27 million to 0.31 million shares. And Virtu Financial BD LLC has lifted its position by 31.99% or 27161.0 shares – to 0.11 million shares.

    With over 2.44 million General Moly Inc. (GMO) shares trading Friday and a closing price of $0.14 on the day, the dollar volume was approximately $0.34 million. The shares have shown a positive weekly performance of 10.69% and its price on 08/28/20 gained nearly 1.39%. Currently, there are 152.32M common shares owned by the public and among those 82.74M shares have been available to trade.

    An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for GMO have a consensus price objective of $0.75. The analysts have set the share’s price value over the next 12 months at a high of $0.75 and a low of $0.75 should the stock experience a downside. But an upside of 81.33% will see the stock hit the forecast high price target while mean target price for the stock is $0.75.

    Insiders at the company have transacted a total of 14 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 13,001,111 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 473,592 shares.

    The top 3 mutual fund holders in General Moly Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Bridgeway Ultra Small Company Mar. Vanguard Total Stock Market Index owns 1.63 million shares of the company’s stock, all valued at over $0.36 million. Bridgeway Ultra Small Company Mar bought 0.42 million shares to bring its total holdings to over 0.42 million shares at a value of $91740.0. Bridgeway Ultra Small Company Mar now owns shares totaling to 0.27% of the shares outstanding.

    Shares of General Moly Inc. (AMEX: GMO) opened at $0.12, down -$0.02 from a prior closing price of $0.14. However, the script later closed the day at $0.14, up 1.39%. The company’s stock has a 5-day price change of 10.69% and -25.93% over the past three months. GMO shares are trading -38.94% year to date (YTD), with the 12-month market performance down to -25.66% lower. It has a 12-month low price of $0.10 and touched a high of $0.37 over the same period. Currently, 2.44 million shares have been traded, compared to an average intraday trading volume of 1.35 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.64%, -37.32%, and -35.14% respectively.

    Institutional ownership of General Moly Inc. (AMEX: GMO) shares accounts for 4.90% of the company’s 152.32M shares outstanding. Mutual fund holders own 2.51%, while other institutional holders and individual stakeholders account for 62.00% and 2.10% respectively.

    It has a market capitalization of $20.87M and a beta (3y monthly) value of 0.47. The earnings-per-share (ttm) stands at -$1.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 29.83% over the week and 13.99% over the month.

    Analysts forecast that General Moly Inc. (GMO) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for Next Year. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. EPS should shrink at an annualized rate of 0.00% over the next five years, compared to 13.80% over the past 5-year period.

    Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”

    Looking at the support for the GMO, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on May 19, 2014, with the firm’s price target at $1.70. RBC Capital Mkts coverage for the General Moly Inc. (GMO) stock in a research note released on March 27, 2009 offered a Underperform rating with a price target of $1.30. RBC Capital Mkts was of a view on November 10, 2008 that the stock is Underperform, while Dahlman Rose gave the stock Hold rating on November 05, 2008, issuing a price target of. Friedman Billings on their part issued Mkt Perform rating on August 13, 2008.


    Please enter your comment!
    Please enter your name here